Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory
blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female
subjects, to demonstrate the bioequivalence (BE) between two active product ingredient (API)
sources of eslicarbazepine acetate (ESL)